Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: Findings from the INternational VErapamil-SR/ trandolapril STudy (INVEST)

European Heart Journal

Volumn 29, Issue 10, 2008, Pages 1327-1334

  Kolloch, Rainer ^a   Legler, Udo F ^b   Champion, Annette ^c   Cooper DeHoff, Rhonda M ^d   Handberg, Eileen ^d   Zhou, Qian ^c   Pepine, Carl J ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c ABBOTT LABORATORIES   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse outcomes; Atenolol; Coronary artery disease; INVEST; Resting heart rate; Verapamil SR

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG FATALITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; FEMALE; HEART RATE; HUMANS; HYPERTENSION; INDOLES; MALE; TREATMENT OUTCOME; VERAPAMIL;

EID: 44449129008     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn123     Document Type: Article

References (38)

1. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? Eur Heart J 2006;27:2387-2393.
2. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997;30:1104-1106.
3. Stamler J, Berkson DM, Dyer A, Lepper MH, Lindberg HA, Paul O, McKean H, Rhomberg P, Schoenberger JA, Shekelle RB, Stamler R. Relationship of multiple variables to blood pressure - findings from four Chicago epidemiologic studies. In: O P, ed. Epidemiology and Control of Hypertension. Symposia Specialists, Miami, 1975. p307-352.
4. Eriksson J, Rodahl K. Resting heart rate in apparently healthy middle-aged men. Eur J Appl Physiol 1979;42:61-69.
5. Berenson GS, Voors AW, Webber LS, Dalferes ER Jr, Harsha DW. Racial differences of parameters associated with blood pressure levels in children - the Bogalusa Heart Study. Metabolism 1979;28:1218-1228.
6. Schieken RM, Clarke WR, Lauer RM. Left ventricular hypertrophy in children with blood pressures in the upper quintile of the distribution. The Muscatine Study. Hypertension 1981;3:669-675.
7. Simpson FO, Waal-Manning HJ, Bolli P, Spears GF. The Milton Survey. 2. Blood pressure and heart rate. NZ Med J 1978;88:1-4.
8. Reed D, McGee D, Yano K. Biological and social correlates of blood pressure among Japanese men in Hawaii. Hypertension 1982;4:406- 414.
9. Medalie JH, Kahn HA, Neufeld HN, Riss E, Goldbourt U. Five-year myocardial infarction incidence. II. Association of single variables to age and birthplace. J Chronic Dis 1973;26:325-349.
10. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997;15:3-17.
11. Pickering TG, James GD. Determinants and consequences of the diurnal rhythm of blood pressure. Am J Hypertens 1993;6:166S-169S.
12. Kannel WB, Wilson P, Blair SN. Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985;109:876-885.
13. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-1494.
14. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension 1997;30:1267-1273.
15. Palatini P. Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens Suppl 1999;17:S3-S10.
16. Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 1999;159:585-592.
17. Palatini P. Heart rate as a cardiovascular risk factor: do women differ from men? Ann Med 2001;33:213-221.
18. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O'Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002;162:2313-2321.
19. Disegni E, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Zion M, Boyko V, Behar S. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Clin Epidemiol 1995;48:1197-1205.
20. Palatini P. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs. Drugs 1999;57:713-724.
21. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J 2005;26:943-945.
22. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P. Rationale and design of the International Verapamil-SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998;32:1228-1237.
23. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-2446.
24. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
25. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-SR/Trandolapril Study (INVEST): a randomized controlled trial. J Am Med Assoc 2003;290:2805-2816.
26. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-2567.
27. Marchioli R, Avanzini F, Barzi F, Chieffo C, Di Castelnuovo A, Franzosi MG, Geraci E, Maggioni AP, Marfisi RM, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Valagussa F. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001;22:2085-2103.
28. Steffenino G, Santoro GM, Maras P, Mauri F, Ardissino D, Violini R, Chiarella F, Lucci D, Marini M, Baldasseroni S, Maggioni AP. In-hospital and one-year outcomes of patients with high-risk acute myocardial infarction treated with thrombolysis or primary coronary angioplasty. Ital Heart J 2004;5:136-145.
29. Nul DR, Doval HC, Grancelli HO, Varini SD, Soifer S, Perrone SV, Prieto N, Scapin O. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentricos en Argentina. J Am Coll Cardiol 1997;29:1199-1205.
30. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Ryden L. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003;89:42-48.
31. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974.
32. Kristal-Boneh E, Silber H, Harari G, Froom P. The association of resting heart rate with cardiovascular, cancer and all-cause mortality: eight-year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2000;21:116-124.
33. Lefrandt JD, Heitmann J, Sevre K, Castellano M, Hausberg M, Fallon M, Fluckiger L, Urbigkeit A, Rostrup M, Agabiti-Rosei E, Rahn KH, Murphy M, Zannad F, de Kam PJ, van Roon AM, Smit AJ. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001;14:1083- 1089.
34. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-785.
35. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, Held C, Nasman P, Wallen NH. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996;17:76-81.
36. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998;21:633-641.
37. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-1689.
38. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553.